Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

Shares of CVS Health Corporation (CVS) traded 10% higher in pre-market on Thursday after the company reported better-than-expected first-quarter (Q1) earnings and raised its full-year profit guidance.

CVS (CVS) reported first quarter earnings Thursday, beating Wall Street's expectations. The company also raised its full-year 2025 guidance, with adjusted earnings per share now expected in the ...

CVS Health (NYSE: CVS) raised its full-year 2025 adjusted EPS guidance to a range of $6.00 to $6.20, up from its previous forecast of $5.75 to $6.00 and above the analyst consensus of $5.91.

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my analysis on CVS stock's earnings here.

CVS Health Corp posted a strong first quarter in 2025, with earnings per share (EPS) of $2.25, surpassing the forecast of $1.64. The company’s revenue reached nearly $95 billion, exceeding ...

CVS Health reported robust year-over-year growth in Q1 2025 earnings, with significant increases in sales, revenue, and net income, though the company adjusted its annual earnings guidance downward.

Activist investor Glenview Capital is reducing its stake in healthcare giant CVS Health following its first-quarter earnings ...

Full Year Cash Flow Guidance: Updated to approximately $7 billion. CVS Health Corp (NYSE:CVS) reported strong financial results for Q1 2025, with adjusted earnings per share of $2.25 and adjusted ...

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare Advantage headwinds.

CVS Health Corp posted a strong first quarter in 2025, with earnings ... guidance to $6.00-$6.20. Stock price increased by 8.8% in premarket trading. Strategic partnerships and innovations are driving ...